Table ASummary of strength of evidence of efficacy, by drug and condition

– generalized anxiety disorder-++--
– social phobia+-
Attention Deficit/Hyperactivity Disorder
-no co-occurring disorders+
Attention Deficit/Hyperactivity Disorder
-bipolar children-
Attention Deficit/Hyperactivity Disorder
-mentally retarded children+
Dementia overall++++++
Dementia psychosis++-+-++
Dementia agitation++++-++
-MDD augmentation of SSRI/SNRI Image executivesummaryfu1.jpg Image executivesummaryfu2.jpg Image executivesummaryfu3.jpg+++
-MDD: Monotherapy-++
Eating Disorders---
Obsessive Compulsive Disorder
-augmentation of SSRI+--++-
Obsessive Compulsive Disorder
-augmentation of citalopram++
Personality Disorder
Personality Disorder
Post Traumatic Stress Disorder+-+++
Substance Abuse alcohol----
Substance Abuse cocaine--
Substance Abuse methamphetamine-
Substance Abuse methadone clients-
Tourette's Syndrome+-

Image executivesummaryfu4.jpg moderate or high evidence of efficacy

Image executivesummaryfu5.jpg low or very low evidence of efficacy

Image executivesummaryfu6.jpg mixed results

Image executivesummaryfu7.jpg low or very low evidence of inefficacy

Image executivesummaryfu8.jpgmoderate or high evidence of inefficacy

○ : no trials

Image executivesummaryfu9.jpg: Approved by FDA for the indication

MDD = major depressive disorder; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitors

Note: Symbols denote strength of evidence, not size of portential effect. For example in dementia “++” indicates moderate-to-high strength of evidence that there is a beneficial effect, however the size of the effect is small.

From: Executive Summary

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.